CDH2 and neoplasm: Patients stratified by combined CDH2^high/miR-210^high expression could be prioritized for RAX-targeted intervention trials, analogous to PD-L1 or tumor mutational burden (TMB)-based enrichment in immunotherapy trials [176,177,241,242,243,244,245].